Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 4/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387076 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2PDE4DCREBBPMAOBMAOA | |
| SCHEMBL13535958 | 0.87 | TTR (0.57) | PDE4DCREBBPTTRALBHPGD | |
| SCHEMBL22342481 | 0.87 | CREBBP (0.61) | SMN1; SMN2CREBBPMAOBMAOAHDAC1 | |
| SCHEMBL9662476 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2PDE4DCREBBPMAOBHDAC1 | |
| SCHEMBL26740126 | 0.84 | TTR (0.46) | SMN1; SMN2CREBBPMAOBMAOATTR | |
| SCHEMBL13535957 | 0.84 | TTR (0.59) | PDE4DMAOATTRALBHSD17B10 | |
| SCHEMBL18374265 | 0.84 | PDE4D (0.43) | SMN1; SMN2PDE4DTTRALBL3MBTL1 | |
| SCHEMBL17480174 | 0.83 | MAOB (0.48) | SMN1; SMN2CREBBPMAOBMAOATTR | |
| SCHEMBL18374370 | 0.81 | SCN9A (0.50) | SMN1; SMN2MAOBMAOATTRALB | |
| SCHEMBL27197622 | 0.81 | MAOB (0.44) | SMN1; SMN2CREBBPMAOBMAOAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| WO-2018128720-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | WO | disclosed |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| WO-2018098208-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098207-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098207-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2017006282-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | SMN1; SMN2 3820/4885PDE4D 2361/4885CREBBP 3551/4885 |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | SMN1; SMN2 3820/4885PDE4D 2361/4885CREBBP 3551/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | SMN1; SMN2 3100/4885PDE4D 3237/4885CREBBP 3654/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | SMN1; SMN2 3547/4885PDE4D 2923/4885CREBBP 2339/4885 |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | SMN1; SMN2 3820/4885PDE4D 2361/4885CREBBP 3551/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | SMN1; SMN2 3820/4885PDE4D 2361/4885CREBBP 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.